Related Experiment Video
Updated: May 4, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Cannabinoid hyperemesis syndrome
Shusen Sun1, Anthony E Zimmermann2
1Clinical Assistant Professor.
Background:
The purpose of this review is to describe cannabinoid hyperemesis syndrome (CHS), which is thought to be induced by long-term cannabis use, and provide clinical pharmacists with information to manage the hyperemetic phase of CHS.
Method:
Published literature was searched and reviewed using PubMed.
Results:
CHS is characterized by intractable nausea and vomiting without an obvious organic cause and associated learned compulsive hot water bathing behavior. Patients often seek care in the emergency department (ED) for symptomatic relief.
Conclusion:
CHS is potentially underrecognized and underdiagnosed in the ED, and it should be considered in the differential diagnosis in long-term cannabis use patients with CHS symptoms to avoid unnecessary extensive diagnostic workup including invasive radiologic imaging. Pharmacists have an important role in CHS recognition, education, and symptom management.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Hyperosmolar Hyperglycemic State
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Pathophysiology of Vomiting
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

